---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265707"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:21:22.840481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q3 net loss narrows to $13.9M; cash $117.6M supports ops into 2028

## Summary
- Net loss of $13.9M vs $16.5M in Q3 2024; R&D expenses $10.7M (down 24% YoY).
- Cash, cash equivalents and short-term investments of $117.6M as of Sept 30, 2025.
- Enrollment ongoing in BBI-355/BBI-825 combination arm of POTENTIATE trial.
- IND submission for BBI-940 on track; Phase 1 trial expected in H1 2026.
- Cash runway into first half of 2028 through proof-of-concept clinical readouts.

## SEC filing metadata
- accession: 0001193125-25-265707
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/0001193125-25-265707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000119312525265707/bold-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265707
- JSON: https://secwatch.observer/filing/0001193125-25-265707.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.